Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
drugs
3
×
life sciences
national blog main
alnylam pharmaceuticals
boston
boston top stories
rna interference
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
alirocumab
allergic conjunctivitis
amgen
aminolevulinic acid
biotech
dry eye disease
evercore isi
evolocumab
givosiran
heart attack
inclisiran
joseph swartz
medicines co.
new york
new york blog main
new york top stories
pcsk9 inhibitors
regeneron pharmaceuticals
reproxalab
sjogren-larsson syndrome
stroke
svb leerink
umer raffat
What
data
3
×
drug
new
3
×
alnylam
medicine
pharmaceuticals
rna
aldeyra
based
cholesterol
cleared
closer
disclosed
evidence
eye
far
fda
fighting
filing
heart
inflammation
interference
lasting
long
looms
lowering
market
medco
medicines
multiple
nasdaq
ok
partner
phase
positive
presented
puts
reckoning
results
rnai
Language
Current search:
drugs
×
new
×
data
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug